Regene Med regenemed.com


Public lists: Pharma Startups (4740)

RegeneMed, Inc. is accelerating the development of safer, more effective drugs by providing integrated high throughput platforms incorporating engineered human tissue-based assays. RegeneMed possesses patented, proprietary, core technologies enabling the in vitro growth of engineered human tissues, including liver, GI tract, bone marrow and blood-brain barrier. These tissue-based in vitro model systems will accelerate drug development and aims to debottleneck ADME/Tox evaluation, the leading cau...Show all

RegeneMed, Inc. is accelerating the development of safer, more effective drugs by providing integrated high throughput platforms incorporating engineered human tissue-based assays. RegeneMed possesses patented, proprietary, core technologies enabling...Show all

Company (Alive / Active)

Phone: 858-200-9530

Fax:

9855 Towne Centre Drive
Suite 200
San Diego, 92121
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Regene Med $1M Jul 5, 2007
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Regene Med Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 2 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

NeuroGenomeX

Madison, Wisconsin, United States
Alive / ActiveNeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in...Show allLogin to see details

BioDelivery Sciences International

Raleigh, North Carolina, United States
IPO / Went publicBioDelivery Sciences (BDSI) is a specialty pharmaceutical company<br/><br/><br/><br/>that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.<br/><br/><br/><br/>The development strategy focuses on utilization of the FDA's 505(b)(2) approval process to potentially obtain timely and efficient app...Show allLogin to see details
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)